AnaptysBio Inc (ANAB) Sees Significant Increase in Short Interest

AnaptysBio Inc (NASDAQ:ANAB) was the target of a significant growth in short interest in December. As of December 29th, there was short interest totalling 1,387,012 shares, a growth of 40.3% from the December 15th total of 988,390 shares. Based on an average trading volume of 280,607 shares, the short-interest ratio is presently 4.9 days. Currently, 9.8% of the shares of the company are short sold.

A number of institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC grew its stake in AnaptysBio by 3.2% during the third quarter. Perceptive Advisors LLC now owns 982,269 shares of the biotechnology company’s stock worth $34,330,000 after buying an additional 30,000 shares in the last quarter. VHCP Management II LLC acquired a new stake in AnaptysBio during the third quarter worth about $5,856,000. Evercore Wealth Management LLC acquired a new stake in AnaptysBio during the third quarter worth about $100,000. California State Teachers Retirement System grew its stake in AnaptysBio by 104.2% during the third quarter. California State Teachers Retirement System now owns 19,400 shares of the biotechnology company’s stock worth $678,000 after buying an additional 9,900 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of AnaptysBio by 69.3% in the third quarter. Schwab Charles Investment Management Inc. now owns 32,846 shares of the biotechnology company’s stock worth $1,148,000 after acquiring an additional 13,444 shares during the last quarter. Hedge funds and other institutional investors own 75.48% of the company’s stock.

Shares of AnaptysBio (NASDAQ ANAB) opened at $112.40 on Friday. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio has a one year low of $15.17 and a one year high of $114.47.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. equities analysts forecast that AnaptysBio will post -1.72 earnings per share for the current year.

Several research firms recently commented on ANAB. Wedbush restated an “outperform” rating and issued a $75.00 price target (up from $37.00) on shares of AnaptysBio in a research note on Friday, October 13th. Jefferies Group began coverage on shares of AnaptysBio in a research note on Thursday, November 9th. They issued a “buy” rating and a $101.00 price target on the stock. JMP Securities upped their price target on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Stifel Nicolaus restated a “buy” rating and issued a $76.00 price target (up from $35.00) on shares of AnaptysBio in a research note on Friday, October 13th. Finally, Robert W. Baird set a $69.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a research note on Wednesday, October 11th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $88.00.

COPYRIGHT VIOLATION WARNING: “AnaptysBio Inc (ANAB) Sees Significant Increase in Short Interest” was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2018/01/14/anaptysbio-inc-anab-sees-significant-increase-in-short-interest.html.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply